Structure Therapeutics Inc. American Depositary Shares (GPCR · NASDAQ)

GPCR · MARKET VIEW

Market view · as of Jun 1, 2026

Revenue (TTM)
$0
0.0% YoY
EPS (latest q)
$-0.35
vs $-0.35 est · in line
52-wk position
28.8%
-58.9% vs 52w high · -8.7% 1mo

Price (last ~year)

Structure Therapeutics (GPCR) shares have declined 35.4% over the past three months to close at $38.55, currently trading 17.6% below the 200-day moving average. The clinical-stage biopharmaceutical company reported zero TTM revenue and a $76.2 million net loss for the quarter ending March 31, 2026. As of that date, the firm held $316.2 million in cash against $5.8 million in total debt, supporting a market capitalization of $2.80 billion.

Valuation

Market cap
$2.80B
P/B
1.932
EV/EBITDA
-13.46
Beta
-1.39
Analyst target
$106.47

Quality & returns

Operating margin
0.0%
Profit margin
0.0%
ROE
-11.9%
ROA
-9.4%

Price movement

Last
$38.55
1-month
-8.7%
3-month
-35.4%
RSI (14)
51
vs SMA200
-17.6%
52-wk position
28.8% -58.9% vs high

Quarterly trajectory

Revenue by quarter (oldest → newest)

QuarterRevenueOp incomeNet incomeEBITDA
2026-03-31$0$-89.6M$-76.2M$-88.4M
2025-12-31$0$24.0M$33.0M$33.6M
2025-09-30$0$-73.8M$-65.7M$-65.3M
2025-06-30$0$-70.5M$-61.7M$-70.2M

Recent news

Sources this view read

  • fundamentals Company overview & valuation (Alpha Vantage OVERVIEW)
  • filing Quarterly financial statements (Alpha Vantage INCOME/BALANCE/CASH)
  • earnings Reported earnings history (Alpha Vantage EARNINGS)
  • prices Adjusted daily prices (Alpha Vantage TIME_SERIES_DAILY_ADJUSTED)